02 October 2024
02 October 2024
Genentech鈥檚 parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including oncology.
Otulfi is the fourth Stelara biosimilar approved in the US but will not launch until early 2025.
The 12th Annual Outsourcing in Clinical Trials & Clinical Trial Supply Nordics conference provided a venue to discuss the ideal criteria for CDMO partnerships.
As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime Medicine.
Clinical trials demonstrated that RAPIVAB is effective against mostly influenza A and some influenza B infections.
Epigenetic drugs induce heritable modifications to genetic material that result in changes in gene expression without altering the DNA sequence.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
